Interferon alfacon-1

Generic Medicine Info
Indications and Dosage
Chronic hepatitis C
Adult: 9 mcg 3 times/wk for 24 wk followed by 15 mcg 3 times/wk for up to 48 wk if needed.
Hypersensitivity. Hepatic decompensation, autoimmune hepatitis.
Special Precautions
History of severe psychiatric disorders (monitor for signs of depression). Preexisting or history of cardiac disease. Perform periodic ophthalmologic exam in patients with preexisting ophthalmologic disorders (e.g. diabetic or hypertensive retinopathy). Autoimmune disorders. History of endocrine disorders. Abnormally low peripheral blood cell counts or concurrent myelosuppressive therapy. Transplantation or chronically immunosuppressed patients. Monitor haematological and thyroid functions before therapy, 2 wk after initiation and periodically thereafter. Elderly. Children (not recommended). Pregnancy, lactation. Withhold dose in patients who experience a severe adverse reaction, stop or decraese treatment if the reaction does not become tolerable.
Adverse Reactions
Insomnia, nervousness, depression, dizziness, anxiety, emotional lability; alopecia, pruritus, rash; hot flushes; GI disturbances; blood dyscrasia; inj site reactions; myalgia, arthralgia, pain, paraesthesia; flu-like symptoms; upper respiratory tract infection; chest pain, arrhythmia, MI; hypersensitivity reaction; blurred or loss of vision; hepatomegaly, liver tenderness.
Parenteral/SC: C
Symptoms include anorexia, chills, fever, myalgia and elevated LFTs.
Drug Interactions
Enhanced myelosuppression with other myelosuppressive drugs. Drugs metabolised via the CYP450 pathway (monitor for changes in pharmacologic or adverse effects of concomitant drug).
Mechanism of Action: Interferon alfacon-1 has antiviral, antiproliferative and immune-regulating effects. It induces gene transcription, inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell-surface antigen expression, increases phagocytic activity of macrophages and augments cytotoxicity of lymphocytes for target cells.
Store in a refrigerator at 2-8°C (36-46°F).
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Interferon alfacon-1 from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in